Chimeric Therapeutics LimitedASX: CHM

Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA

Jun 5, 2024 at 3:32 AM UTC · Issued by Chimeric Therapeutics Limited

Chimeric Therapeutics Ltd has released a press release.

View Attachment